Point72 Asset Management’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,663,339
| Closed | -$79M | – | 3878 |
|
|
2025
Q3 | $79M | Sell |
1,663,339
-1,047,590
| -39% | -$50.7M | 0.13% | 170 |
|
|
2025
Q2 | $145M | Buy |
2,710,929
+2,202,589
| +433% | +$100M | 0.28% | 69 |
|
|
2025
Q1 | $20.6M | Sell |
508,340
-391,340
| -43% | -$16.6M | 0.05% | 446 |
|
|
2024
Q4 | $25M | Sell |
899,680
-403,643
| -31% | -$12.2M | 0.06% | 386 |
|
|
2024
Q3 | $37.4M | Buy |
+1,303,323
| New | +$34M | 0.1% | 249 |
|
|
2024
Q2 | – | Sell |
-289,106
| Closed | -$7.3M | – | 1817 |
|
|
2024
Q1 | $7.3M | Sell |
289,106
-355,199
| -55% | -$8.53M | 0.02% | 842 |
|
|
2023
Q4 | $15M | Buy |
644,305
+605,705
| +1,569% | +$11.9M | 0.04% | 543 |
|
|
2023
Q3 | $1.95M | Buy |
+38,600
| New | +$1.8M | 0.01% | 1137 |
|
|
2022
Q3 | – | Sell |
-2,300,000
| Closed | -$21.7M | – | 1384 |
|
|
2022
Q2 | $21.7M | Buy |
2,300,000
+453,000
| +25% | +$4.72M | 0.09% | 294 |
|
|
2022
Q1 | $26.2M | Buy |
1,847,000
+88,499
| +5% | +$1.55M | 0.1% | 260 |
|
|
2021
Q4 | $37.2M | Buy |
1,758,501
+360,101
| +26% | +$7.99M | 0.15% | 187 |
|
|
2021
Q3 | $31.3M | Buy |
1,398,400
+206,700
| +17% | +$4.68M | 0.14% | 201 |
|
|
2021
Q2 | $29.6M | Buy |
1,191,700
+685,203
| +135% | +$19.2M | 0.13% | 199 |
|
|
2021
Q1 | $14.7M | Sell |
506,497
-198,503
| -28% | -$6.01M | 0.07% | 335 |
|
|
2020
Q4 | $18.2M | Buy |
705,000
+561,861
| +393% | +$15.6M | 0.09% | 301 |
|
|
2020
Q3 | $4.41M | Sell |
143,139
-301,893
| -68% | -$10.6M | 0.02% | 588 |
|
|
2020
Q2 | $11.1M | Sell |
445,032
-280,213
| -39% | -$6.4M | 0.07% | 310 |
|
|
2020
Q1 | $15.4M | Buy |
725,245
+498,945
| +220% | +$10.7M | 0.12% | 240 |
|
|
2019
Q4 | $5.02M | Buy |
226,300
+119,600
| +112% | +$2.47M | 0.03% | 496 |
|
|
2019
Q3 | $2.43M | Buy |
106,700
+76,700
| +256% | +$1.78M | 0.01% | 566 |
|
|
2019
Q2 | $575K | Buy |
+30,000
| New | +$569K | ﹤0.01% | 821 |
|
Other funds holding AKRO
Point72 Asset Management's AKRO Position: Q4 2025 in Review
Point72 Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 1,663,339 shares — an estimated $79M sold.
Point72 Asset Management first reported a position in AKRO in Q2 2019 and held it in 21 quarters. The position peaked at $145M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Point72 Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Point72 Asset Management sold 1,663,339 Akero Therapeutics shares in Q4 2025, an estimated $79M.
- Point72 Asset Management first reported a position in Akero Therapeutics in Q2 2019 and held it in 21 quarters.
- Point72 Asset Management's Akero Therapeutics position peaked at $145M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Point72 Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.